Dramowski Angela, Ong'ayo Gerald, Rehman Andrea M, Whitelaw Andrew, Labi Appiah-Korang, Obeng-Nkrumah Noah, Ndir Awa, Magwenzi Marcelyn T, Onyedibe Kenneth, Wolkewitz Martin, de Kraker Marlieke E A, Scott J Anthony G, Aiken Alexander M
Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya.
JAC Antimicrob Resist. 2021 Jan 19;3(1):dlaa130. doi: 10.1093/jacamr/dlaa130. eCollection 2021 Mar.
Bloodstream infections (BSI) caused by Enterobacteriaceae show increasing frequency of resistance to third-generation cephalosporin (3GC) antibiotics on the African continent but the mortality impact has not been quantified.
We used historic data from six African hospitals to assess the impact of 3GC resistance on clinical outcomes in and BSI. We matched each bacteraemic patient to two uninfected patients. We compared outcomes between 3GC-susceptible and 3GC-resistant BSI and their respective uninfected controls using Cox regression models.
For 1431 BSI patients, we matched 1152 (81%) 3GC-susceptible and 279 (19%) 3GC-resistant cases to 2263 and 546 uninfected inpatient controls. For 1368 BSI patients, we matched 502 (37%) 3GC-susceptible and 866 (63%) 3GC-resistant cases to 982 and 1656 uninfected inpatient controls. We found that 3GC-resistant had similar hazard ratios (HRs) for in-hospital mortality over their matched controls as compared to susceptible infections over their controls (ratio of HRs 1.03, 95% CI 0.73-1.46). Similarly, 3GC-resistance in BSI was not associated with mortality (ratio of HR 1.10, 95% CI 0.80-1.52). Estimates of mortality impact varied by site without a consistent pattern.
In a retrospective analysis, including the use of matched uninfected patients, there did not appear to be an impact of 3GC-resistance on mortality in or BSI in African hospitals, as compared with susceptible BSI with equivalent species. Better information on the actual use of antibiotics in treating infections in African hospitals would improve these impact estimates.
在非洲大陆,由肠杆菌科细菌引起的血流感染(BSI)对第三代头孢菌素(3GC)类抗生素的耐药频率不断增加,但尚未对其死亡率影响进行量化。
我们使用来自六家非洲医院的历史数据,评估3GC耐药性对成人和儿童BSI临床结局的影响。我们将每位菌血症患者与两名未感染患者进行匹配。我们使用Cox回归模型比较了对3GC敏感和耐药的BSI及其各自未感染对照之间的结局。
对于1431例成人BSI患者,我们将1152例(81%)对3GC敏感和279例(19%)对3GC耐药的病例与2263例和546例未感染的住院对照进行匹配。对于1368例儿童BSI患者,我们将502例(37%)对3GC敏感和866例(63%)对3GC耐药的病例与982例和1656例未感染的住院对照进行匹配。我们发现,与对照中敏感感染相比,对3GC耐药的成人在院内死亡的风险比(HRs)与其匹配对照相似(HRs之比为1.03,95%CI为0.73 - 1.46)。同样,儿童BSI中的3GC耐药与死亡率无关(HR之比为1.10,95%CI为0.80 - 1.52)。死亡率影响的估计因地点而异,没有一致的模式。
在一项包括使用匹配的未感染患者的回顾性分析中,与同等菌种的敏感BSI相比,3GC耐药性在非洲医院的成人或儿童BSI中似乎对死亡率没有影响。关于非洲医院治疗感染时抗生素实际使用情况的更好信息将改善这些影响估计。